评估重复正电子发射断层成像对疑似心脏结节病患者治疗反应及心血管结局的影响:一个接受统一治疗的队列
研究纳入81例疑似心脏结节病且基线PET显示炎症、未用免疫抑制治疗的患者,均接受中等剂量泼尼松单药治疗并复查PET。按复查间隔三分位分组,各组治疗反应率、减量速率及1年累积泼尼松剂量相似,短期主要不良心血管事件无显著差异。结论认为监测间隔和减量速率似乎不影响PET治疗反应。
要点
- 81例疑似心脏结节病患者接受泼尼松30-40 mg/日单药治疗后复查PET,按复查间隔三分位分组。
- 治疗反应率三分位组间相似: tertile-1 92% vs tertile-2 86.2% vs tertile-3 85.2%(P = .76)。
- 短期主要不良心血管事件在三分位组间(P = .89)及按治疗反应状态(P = .39)均无显著差异。
核心结论
- 监测间隔时间和减量速率似乎不影响仅接受中等剂量泼尼松治疗的疑似心脏结节病患者PET扫描上的治疗反应。
- 尽管随访时间和治疗反应状态存在差异,观察到的主要不良心血管事件发生率相似。
研究设计与样本
- 研究识别了81例疑似心脏结节病患者(年龄56.3 ± 1.9岁,67%为男性,左心室射血分数46.5 ± 3),基线PET显示炎症且未接受免疫抑制治疗。
- 患者随后开始中等剂量泼尼松单药治疗(即30-40 mg/日),并进行了诊断性随访PET。
- 治疗反应分级为完全治疗反应(CTR)或部分治疗反应(PTR)对比无反应。
- 患者根据PET扫描间随访时间分为三分位:三分位-1(<3.2个月;中位数3.1个月)、三分位-2(3.2-6.8个月;中位数5.9个月)、三分位-3(>6.8个月;中位数9.8个月)。
- 通过测量从治疗开始至长达一年随访期间泼尼松的每周变化来捕捉皮质类固醇减量。
主要发现
- 治疗反应CTR/PTR率在各三分位间相似:三分位-1 92% vs 三分位-2 86.2% vs 三分位-3 85.2%(P = .76)。
- 减量速率和一年累积泼尼松剂量在三组间相似(P = .9)。
- 三分位组间短期主要不良心血管事件无显著差异(P = .89)。
- 主要不良心血管事件按治疗反应状态也无显著差异(P = .39)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Serial positron emission tomography (PET) imaging is routinely used to monitor treatment response in patients with suspected cardiac sarcoidosis (CS). Corticosteroids remain the mainstay of therapy in CS. However, there are no data available on the cardiovascular outcomes and optimal timing interval to obtain repeat PET while factoring in the influence of corticosteroid taper in relation to surveillance imaging. METHODS: We identified 81 patients with suspected CS (age: 56.3 ± 1.9, 67% male, left ventricle ejection fraction: 46.5 ± 3) who were not on immunosuppression treatment and demonstrated inflammation on baseline PET, subsequently started on moderate-dose prednisone monotherapy (i.e., 30-40 mg/day), and had a diagnostic follow-up PET. Treatment response was graded as complete treatment response (CTR) or partial treatment response (PTR) vs no response. Patients were divided into tertiles based on follow-up time between PET scans; tertile-1 (<3.2 months; median: 3.1 months), tertile-2 (3.2-6.8 months; median: 5.9 months), and tertile-3 (>6.8 months; median: 9.8 months). Corticosteroid taper was captured by measuring weekly changes in prednisone from the start of treatment to up to one-year follow-up. Major adverse cardiovascular events (MACEs), defined as sustained ventricular arrhythmias, were documented during the first year post baseline PET. RESULTS: Treatment response CTR/PTR rates were similar across tertiles: (tertile-1 [92%] vs tertile-2 [86.2%] vs tertile-3 [85.2%]; P = .76). Taper rates and one-year cumulative prednisone dose were similar between the three groups (P = .9). No significant difference was found in short-term MACEs between the tertile groups (P = .89). Similarly, MACEs did not differ significantly according to treatment response status (P = .39). CONCLUSIONS: Surveillance time and taper rates do not seem to influence treatment response on PET scans among patients initiated on moderate-dose prednisone only. Similar MACE rates were observed despite variations in follow-up time and treatment response status.
引用
- Rojulpote C, Bhattaru A, Patil S, et al. Assessing the effect of repeat positron emission tomography imaging on treatment response and cardiovascular outcomes among a homogenously treated cohort of patients with suspected cardiac sarcoidosis. J Nucl Cardiol. 2024. PMID: 39579922. doi:10.1016/j.nuclcard.2024.102082
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。